Moderna falls 18% after cancer trial data leaks

A Phase 3 melanoma study met its primary goal with a 42% risk reduction, trailing earlier results and triggering a sharp sell-off.

Moderna shares fell 17.57% on October 22 after clinical results from a late-stage trial of its personalized messenger RNA cancer vaccine appeared on a medical website ahead of an official conference presentation.¹² The stock dropped as much as 26% during the trading day before closing at $202.63 in New York.¹³² The sell-off wiped out a portion of the company's run-up during 2026, which had lifted its market valuation to roughly $98 billion on October 21.²

The Phase 3 trial evaluated intismeran autogene, an individualized therapeutic vaccine developed jointly with Merck.²¹ The trial enrolled 1,137 patients with high-risk stage 2B to stage 4 melanoma whose tumors had been surgically removed.¹² Patients received the vaccine together with Merck's immunotherapy drug Keytruda, or Keytruda alone with a placebo.² The regimen reduced the relative risk of recurrence or death by 42% compared with Keytruda monotherapy, yielding a hazard ratio of 0.58.¹² It also reduced the risk of cancer spreading to distant organs or death by 38%.²⁴

At the two-year mark, 82.2% of patients in the combination group remained alive without cancer recurrence, compared with 70.0% of patients who received Keytruda alone.² Distant metastasis-free survival reached 88.5% in the combination group compared with 80.2% in the monotherapy group.² Serious side effects occurred in 14.2% of patients receiving both drugs, compared with 13.4% of those receiving Keytruda alone.²

The gap between trial data and market expectations

The market reaction reflected expectations set by earlier data rather than clinical failure. In August 2026, Moderna announced that the Phase 3 trial had met its primary endpoint, but the company withheld specific efficacy numbers until the European Society for Medical Oncology congress in Madrid.³¹ That announcement sparked a buying surge, sending Moderna shares up 177% in a single session on August 19.¹ Between that release and October 21, the stock rose nearly fourfold.²

Earlier findings from the Phase 2 KEYNOTE-942 trial had shown a 49% reduction in the risk of recurrence or death at five years of follow-up.²⁴ When the leaked Phase 3 figures showed a 42% reduction, investors responded by selling.³¹ RBC Capital Markets analyst Trung Huynh observed in a research note that the primary efficacy outcome landed at the low end of investor expectations, even while remaining clinically meaningful.⁴

Evan Seigerman, an analyst at BMO Capital Markets, noted that the reduction in recurrence and death represented a solid clinical outcome.¹ He stated that the decline in the share price reflected expectations that had run too high into the release rather than an underlying deficiency in the drug's performance.¹⁵

Trial design differences and immune timing

Oncologists pointed to structural differences between the two clinical studies to explain the divergence in percentage points. The Phase 2 trial evaluated 157 patients with stage 3 and stage 4 melanoma in an open-label format where participants and physicians knew which treatment was administered.² The Phase 3 trial enrolled 1,137 patients across a wider range of disease severity, including stage 2B, and used a blinded placebo control.²

Dr. George Ansstas, who leads the melanoma department at Washington University in St. Louis and participated as an investigator on both trials, said the enrollment of patients with lower baseline risk profiles naturally influenced the measured relative benefit.⁴ Because patients with less advanced disease have lower baseline recurrence rates, relative risk reductions can appear smaller.⁴ Ansstas described the overall dataset as consistent with earlier findings.⁴

The Phase 3 data also revealed a distinct timeline for treatment efficacy. During the first six months, when patients received their initial injections, researchers observed no difference in recurrence or death rates between the combination group and the monotherapy group.²⁴ After that initial six-month period, the risk reduction widened significantly.

In an analysis isolated to the period after six months, the combination treatment reduced the risk of recurrence or death by 58% and cut the risk of distant metastasis or death by 50%.²⁵ When investigators excluded patients who never received a single dose of the vaccine or placebo, the overall risk reduction reached 49%.² Ansstas suggested that the delay reflects the biological reality of personalized immunotherapy.⁴ Manufacturing each customized batch takes roughly six weeks, and the patient's immune system requires repeated stimulation to build an active defense against tumor neoantigens.⁴⁵

Clinical specialists emphasize long-term stakes

Melanoma physicians viewed the study as a notable development for post-surgical care. Standard treatment protocols often administer Keytruda as an adjuvant therapy after surgery to lower the risk that residual malignant cells form secondary tumors. Preventing distant metastasis to the lungs, liver, or brain is critical because metastatic melanoma carries lower survival rates and requires aggressive intervention.

Dr. Janice Mehnert, a skin cancer specialist at NYU Langone and an investigator on the trial, pointed out that this is the first time adding an agent to immunotherapy has demonstrated an increase in efficacy over Keytruda alone.⁴ Dr. Sekwon Jang, a melanoma specialist at Inova Schar Cancer Institute, said the combination had the potential to become a standard treatment for melanoma patients who undergo surgery without prior immunotherapy.⁴

Dr. Hussein Tawbi, an investigator at the University of Texas MD Anderson Cancer Center, highlighted the safety profile of the vaccine, noting that its side effects consisted primarily of mild reactions like injection-site pain.⁴⁵ Dr. Michael Postow, chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, said that preventing recurrence in earlier stages spares patients from the difficulties of treating metastatic disease.⁴

Manufacturing bottlenecks and portfolio expansion

Despite clinical optimism, commercialization presents substantial operational hurdles. Intismeran autogene is not an off-the-shelf product. Scientists sequence the DNA of a patient's surgically resected tumor, compare it against normal tissue DNA to identify up to 34 patient-specific mutated proteins called neoantigens, and synthesize an individualized mRNA molecule encapsulated in lipid nanoparticles.²

Dr. Adil Daud, a professor of medicine at the University of California San Francisco and lead investigator on the Phase 3 study, warned that the individualized manufacturing workflow is labor-intensive and cannot rely on stockpiled inventory.⁴ Producing a customized dose requires weeks, creating logistical friction for treatment centers.⁴⁵ Daud noted that patients with unresected tumors may continue to rely on existing preoperative therapies to avoid manufacturing delays.⁴

Moderna chief executive Stéphane Bancel said the company is completing its regulatory application with the goal of securing formal approval in 2027.⁴⁵ Merck paid Moderna an option exercise fee of $250 million in October 2022 to co-develop and commercialize the therapy under an agreement originally established in 2016.² The partners are also testing the vaccine in trials for non-small cell lung cancer, bladder cancer, and renal cell carcinoma.⁴⁵

Dr. Dean Li, president of Merck Research Laboratories, cautioned that expanding beyond melanoma remains an unproven process.⁴⁵ Li noted that achieving success in one cancer type provides no certainty that the platform will succeed across different tumor biology, comparing the accomplishment to cutting down a single tree rather than completing an entire village.⁴⁵

The retail volatility surrounding the leak

The data leak on social media triggered volatility among retail traders who had accumulated leveraged positions during the summer rally. Shane Stoffer, an online trader known as Togi, had previously established a $250,000 call position after seeing widespread bearish sentiment on Moderna in early October. Stoffer followed the stock's 25% advance over the subsequent two weeks but grew concerned that clinical expectations had become excessively priced into the shares.³

When an initial price drop placed his holdings at a loss of nearly $200,000, Stoffer abandoned his initial plan to hold the long position until the scheduled weekend medical conference.³ He closed the long contracts and redirected approximately $500,000 into put options betting against the stock shortly before the embargoed Phase 3 data leaked online.³ The subsequent intraday collapse generated substantial gains on his short position.

The European Society for Medical Oncology initiated an inquiry into how the confidential clinical data appeared prematurely on the medical news website.¹ The organization had scheduled the formal presentation of the trial data for October 24 in Madrid, alongside a concurrent publication in the New England Journal of Medicine.¹² The unexpected disclosure forced Moderna and Merck to issue their official press materials two days early, abruptly closing the gap between speculative market expectations and clinical reality.¹³

Save this story

The record

49 sentences trace to 5 sources.

All 5Documents 1Records 0Reporting 4People 0

1. 1 SE Seoul Economic Daily Third-party reporting · en.sedaily.com · 23 Oct 2026 Moderna Cancer Vaccine Passes Phase 3 but Falls Short of Wall Street Hopes See the source
2. 2 A asiae.co.kr Third-party reporting · asiae.co.kr Moderna Cancer Vaccine Cuts Cancer Recurrence Risk by 42%... Shares Plunge After Results Leak - The Asia Business Daily See the source
3. 3 JF Jackson Fordyce Document · tbpn.substack.com · 23 Oct 2026 The Moderna Miracle Trade See the source
4. 4 C CNBC Third-party reporting · cnbc.com · 23 Oct 2026 Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction See the source
5. 5 C CNBC Third-party reporting · cnbc.com · 22 Oct 2026 Moderna shares plunge after cancer vaccine data leaks — despite positive results See the source